Study Type: Prevention detection risk
https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease
Clinicaltrials.gov identifier:
NCT04472338 (https://clinicaltrials.gov/show/NCT04472338)
Prevention
Screening study for people with a mutation linked to prostate cancer risk
https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer
Clinicaltrials.gov identifier:
NCT03805919 (https://clinicaltrials.gov/show/NCT03805919)
Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation
https://www.facingourrisk.org/research-clinical-trials/study/205/risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women
Clinicaltrials.gov identifier:
NCT05287451 (https://clinicaltrials.gov/show/NCT05287451)
Prevention
Prevention study for women at high risk for ovarian cancer
https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress
Clinicaltrials.gov identifier:
NCT05129605 (https://clinicaltrials.gov/show/NCT05129605)
Prevention
People at high risk for prostate cancer due to an inherited mutation
https://www.facingourrisk.org/research-clinical-trials/study/250/helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care
Clinicaltrials.gov identifier:
NCT05483283 (https://clinicaltrials.gov/show/NCT05483283)
Prevention
Latinas with a high risk of breast cancer
https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families
Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.